Imperial College London
Alternate

ProfessorStuartCook

Faculty of Medicine, Institute of Clinical Sciences

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 3313 1346stuart.cook

 
 
//

Location

 

RF 16Sydney StreetRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sweeney:2023:10.1111/febs.16351,
author = {Sweeney, M and Cook, SA and Gil, J},
doi = {10.1111/febs.16351},
journal = {The Federation of European Biochemical Societies (FEBS) Journal},
pages = {1235--1255},
title = {Therapeutic opportunities for senolysis in cardiovascular disease},
url = {http://dx.doi.org/10.1111/febs.16351},
volume = {290},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cellular senescence within the cardiovascular system has, until recently, been understudied and unappreciated as a factor in the development of age-related cardiovascular diseases such as heart failure, myocardial infarction and atherosclerosis. This is in part due to challenges with defining senescence within post-mitotic cells such as cardiomyocytes. However, recent evidence has demonstrated senescent-like changes, including a senescence-associated secretory phenotype (SASP), in cardiomyocytes in response to ageing and cell stress. Other replicating cells, including fibroblasts and vascular smooth muscle cells, within the cardiovascular system have also been shown to undergo senescence and contribute to disease pathogenesis. These findings coupled with the emergence of senolytic therapies, to target and eliminate senescent cells, have provided fascinating new avenues for management of several age-related cardiovascular diseases with high prevalence. In this review, we discuss the role of senescent cells within the cardiovascular system and highlight the contribution of senescence cells to common cardiovascular diseases. We discuss the emerging role for senolytics in cardiovascular disease management while highlighting important aspects of senescence biology which must be clarified before the potential of senolytics can be fully realized.
AU  - Sweeney,M
AU  - Cook,SA
AU  - Gil,J
DO  - 10.1111/febs.16351
EP  - 1255
PY  - 2023///
SN  - 1742-464X
SP  - 1235
TI  - Therapeutic opportunities for senolysis in cardiovascular disease
T2  - The Federation of European Biochemical Societies (FEBS) Journal
UR  - http://dx.doi.org/10.1111/febs.16351
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000746645500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.16351
UR  - http://hdl.handle.net/10044/1/100470
VL  - 290
ER  -
Download